Participate in a Phase I Clinical Trial

This is a Phase 1 drug–drug interaction (DDI) study designed to understand how TP-3654 behaves in the body when taken together with another medication called phenytoin. Phenytoin is known to affect how the body processes certain medications. The purpose of this study is to evaluate how phenytoin may influence the levels of TP-3654 in the bloodstream, as well as to assess the safety and tolerability of this combination in healthy adults. Nuvisertib (TP-3654) is being developed as a potential treatment for certain cancers.

Compensation up to $11,035 for your time and participation.

Eligibility Criteria

To participate, you must:

• Be a Healthy Adult
• Be 18 to 65 years old
• Have a BMI between 18.5 to 32 kg/m²
• Be a Non-Smokers, Non-Vapers and not used other Tabacco Products
• Have a Good Venous Access

Study Requirements:

• 21 overnight (22 days) stays at the research unit followed by 1 follow up phone call.
• Total: up to $11,035 upon completion